Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,053 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Atopic Dermatitis
Interventions: PF-07242813, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Anaheim, California • Fountain Valley, California • Los Angeles, California + 3 more

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, JNJ-95475939, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Fountain Valley, California • Los Angeles, California • Alpharetta, Georgia + 10 more

Conditions: Atopic Dermatitis
Interventions: RVT-501 0.2% ointment, RVT-501 0.5% ointment, Vehicle ointment; Drug · Other
Lead sponsor: Dermavant Sciences GmbH; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Fremont, California • Los Angeles, California • San Diego, California + 10 more

Conditions: Atopic Dermatitis
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 26
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 21 more

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf); Biological
Lead sponsor: Shire; Industry
Eligibility: 1 Year and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 48
States / cities: Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more

Conditions: Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 72
States / cities: Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more

Conditions: Cryopyrin Associated Periodic Syndrome
Interventions: VTX2735; Drug
Lead sponsor: Zomagen Biosciences Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: San Diego, California • Columbus, Georgia

Conditions: Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
Interventions: IL-1 Trap; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis, Psoriasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: San Diego, California • Denver, Colorado

Conditions: Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions: 124I AT-01; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: Tacrolimus Ointment 0.1%, Protopic® ointment, 0.1%, Placebo of Tacrolimus Ointment; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 18 Years and older
Enrollment: 1,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 60
States / cities: Tempe, Arizona • Anaheim, California • Bell Gardens, California + 43 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more

Conditions: Atopic Dermatitis, Eczema, Food Allergy
Interventions: Evaluating atopy in infants, Evaluating TEWL and STS in adults; Other
Lead sponsor: National Jewish Health; Other
Eligibility: 34 Weeks to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atopic Dermatitis
Interventions: ZK245186, Placebo (vehicle without active ingredient); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 13
States / cities: Anaheim, California • Honolulu, Hawaii • Boise, Idaho + 10 more

Conditions: Urticaria
Interventions: Vitamin D (4,000 IU/day), Vitamin D (400 IU/day), Omalizumab; Dietary Supplement · Drug
Lead sponsor: Selina Gierer, D.O.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Triple Negative Breast Cancer
Interventions: Olaparib Oral Product, Olaparib Oral Product in combination with Durvalumab; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 59
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 9,587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Atopic Dermatitis
Interventions: Biologic therapy versus no biologic therapy; Other
Lead sponsor: DermTech; Other
Eligibility: 1 Year and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: New York, New York • Rochester, New York

Conditions: Hereditary Angioedema
Interventions: Recombinant human C1 inhibitor, Placebo; Biological · Other
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 13 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Tampa, Florida • St Louis, Missouri • Lake Oswego, Oregon

Conditions: Urticaria, Angioedema, Hives, Swelling
Interventions: High Dose Vitamin D3, Low Dose Vitamin D3; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Atopic Dermatitis
Interventions: ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 32
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 29 more

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome
Interventions: Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs, Lipoaspiration; Other
Lead sponsor: Arkansas Heart Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES, Lupus, Atopic Dermatitis
Interventions: baricitinib; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

Interleukin-1 Trap to Treat Autoinflammatory Diseases

Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy

Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

The CARRA Registry

A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis